Chief Science Officer
Dr. Carl Ascoli is currently serving as Chief Science Officer for Rockland Immunochemicals Inc. and has more than 30 years of academic and industrial experience. Dr. Ascoli’s responsibilities involve all divisions of the laboratory including production, research and development, quality control, quality assurance, and technical service. Dr. Ascoli works with a team of scientific team leaders who head each of these groups. Through collaborative efforts, Dr. Ascoli and these team leaders carry out strategic planning, problem-solving, creative thinking, and resource allocation.
Under his guidance, Rockland has developed thousands of primary antibodies against targets involved in cancer and other cell signaling pathways. Many of these antibodies were developed into immunoassays including assays for putative biomarkers for various diseases.
Dr. Ascoli has a Doctorate in Biochemistry from Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ). He received his postdoctoral training in autoimmune diseases focusing on autoantibodies and autoantigens associated with primary biliary cirrhosis from the Wistar Institute in Philadelphia, Pennsylvania.
Facts About Me
- I have a Doctorate in Biochemistry from Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ)
- I received postdoctoral training in autoimmune diseases focusing on autoantibodies and autoantigens associated with primary biliary cirrhosis from the Wistar Institute in Philadelphia, Pennsylvania
- I have developed thousands of research antibodies – in one instance an antibody we developed was included in the payload of experiments on a space shuttle mission.
- I was first to discover PML nuclear bodies within the nucleus using autoimmune serum for visualization
- I was mayor of my town for six years
Top Skills
- Nucleic Acid Biochemistry
- Antibody Purification
- Immunoassay Development
- Post Translational Modifications
- Immunofluorescence Microscopy
Articles
-
Methods for Analysis of siRNA
Learn how ModDetect reagents were validated with FDA-approved drug Lumairan, providing reliable quantification for small interfering (siRNA) -
Bioanalytical Assays for Oligonucleotide Therapeutics
This peer-reviewed manuscript explores anti-PS monoclonal antibodies as universal detection reagents for ONT analysis via IF, ELISA, IHC, and IP. -
Validating Antibodies for Western Blotting
This white paper discusses options for validating antibodies for western blotting. -
Highly Specific and Sensitive Nanoimmunoassay of PARP1: A Toolkit to Measure Cell Death
This poster explores our development of highly sensitive and specific antibodies against PARP1 fragments. -
Production and Characterization of High Coverage, Process Specific Pichia P. HCP Antibodies
Describing the process of developing high coverage, process-specific HCP antibodies for the determination of HCPs in the production of recombinant human protein. -
Localization of HDAC1 using high resolution microscopy
Poster discussing the localization of HDAC1 using high resolution microscopy. -
2D-SDS PAGE Analysis Methods For Determining HCP Coverage Using Process Derived anti-HCP Polyclonal Antibodies
2D-SDS PAGE Analysis Methods For Determining HCP Coverage Using Process Derived anti-HCP Polyclonal Antibodies. -
Methods for Analysis of Oligonucleotide Drugs
Explore the critical role of sensitive analytical assays in advancing antisense oligonucleotide (ASO) drug development.
Publications
- Ascoli, C. A. (2021). Could mutations of SARS-CoV-2 suppress diagnostic detection?. Nature biotechnology
- Ascoli, C. A., & Aggeler, B. (2018). Overlooked benefits of using polyclonal antibodies. BioTechniques
- Kohl, T. O., & Ascoli, C. A. (2017). Immunoassays. Cold Spring Harbor protocols
- Kohl, T. O., & Ascoli, C. A. (2017). Indirect Competitive Enzyme-Linked Immunosorbent Assay (ELISA). Cold Spring Harbor protocols
- Kohl, T. O., & Ascoli, C. A. (2017). Direct Competitive Enzyme-Linked Immunosorbent Assay (ELISA). Cold Spring Harbor protocols
- Kohl, T. O., & Ascoli, C. A. (2017). Immunometric Double-Antibody Sandwich Enzyme-Linked Immunosorbent Assay. Cold Spring Harbor protocols
- Kohl, T. O., & Ascoli, C. A. (2017). Immunometric Antibody Sandwich Enzyme-Linked Immunosorbent Assay. Cold Spring Harbor protocols
- Kohl, T. O., & Ascoli, C. A. (2017). Direct and Indirect Cell-Based Enzyme-Linked Immunosorbent Assay. Cold Spring Harbor protocols
- Kohl, T. O., & Ascoli, C. A. (2017). Indirect Immunometric ELISA. Cold Spring Harbor protocols
- Ascoli, C. A., & Maul, G. G. (1991). Identification of a novel nuclear domain. The Journal of cell biology
- Ascoli, C. A., Link, M. R., Venturo, N., Kuchler, R. J., & Mandeles, S. (1988). Identification of a rosette-enriched chromatin fraction from mouse fibroblast nuclei. Archives of biochemistry and biophysics